Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease

Inna Gaisler-Salomon; Efrat Kravitz; Yulia Feiler; Michal Safran; Anat Biegon; Ninette Amariglio; Gideon Rechavi

doi:10.1016/j.neurobiolaging.2014.02.018

Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease

Inna Gaisler-Salomon, Efrat Kravitz, Yulia Feiler, Michal Safran, Anat Biegon, Ninette Amariglio, Gideon Rechavi

Department of Psychology

Research output: Contribution to journal › Article › peer-review

Abstract

Adenosine to inosine (A-to-I) RNA editing is a base recoding process within precursor messenger RNA, catalyzed by members of the adenosine deaminase acting on RNA (ADAR) family. A notable example occurs at the Q/R site of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor subunit GluA2. Abnormally, low editing at this site leads to excessive calcium influx and cell death. We studied hippocampus and caudate samples from Alzheimer's disease (AD) patients and age-matched healthy controls, using direct sequencing and a high accuracy primer-extension technique to assess RNA editing at the Q/R GluA2 site. Both techniques revealed lower, more variable RNA editing in AD, specific to the hippocampus and the GluA2 site. Deficient editing also characterized the hippocampus of apolipoprotein ε4 allele carriers, regardless of clinical diagnosis. In AD, messenger RNA expression of neuronal markers was decreased in the hippocampus, and expression of the Q/R-site editing enzyme ADAR2 was decreased in caudate. These findings provide a link between neurodegenerative processes and deficient RNA editing of the GluA2 Q/R site, and may contribute to both diagnosis and treatment of AD.

Original language	English
Pages (from-to)	1785-1791
Number of pages	7
Journal	Neurobiology of Aging
Volume	35
Issue number	8
DOIs	https://doi.org/10.1016/j.neurobiolaging.2014.02.018
State	Published - Aug 2014

Bibliographical note

Funding Information:
This work was supported in part by grants from the Flight Attendant Medical Research Institute , The Molecular Basis of Human Disease I-CORE (Israeli Centers of Research Excellence) and by the Israel Science Foundation (grant numbers 365/06 and 1942/08 ), and the Israel Ministry for Science and Technology (Scientific Infrastructure Program). Gideon Rechavi holds the Djerassi Chair in Oncology at the Sackler Faculty of Medicine, Tel Aviv University. The authors thank Noa Eilat for her help with proofreading the manuscript.

Keywords

ADAR
AMPA
Alzheimer's disease
ApoE
Caudate
GluA2
Glutamate
Hippocampus
Neurodegeneration
Postmortem
Primer extension
RNA editing

ASJC Scopus subject areas

General Neuroscience
Aging
Developmental Biology
Clinical Neurology
Geriatrics and Gerontology

Access to Document

10.1016/j.neurobiolaging.2014.02.018

Cite this

@article{eddc56a056244f2f91ad06d2f557a65f,

title = "Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease",

abstract = "Adenosine to inosine (A-to-I) RNA editing is a base recoding process within precursor messenger RNA, catalyzed by members of the adenosine deaminase acting on RNA (ADAR) family. A notable example occurs at the Q/R site of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor subunit GluA2. Abnormally, low editing at this site leads to excessive calcium influx and cell death. We studied hippocampus and caudate samples from Alzheimer's disease (AD) patients and age-matched healthy controls, using direct sequencing and a high accuracy primer-extension technique to assess RNA editing at the Q/R GluA2 site. Both techniques revealed lower, more variable RNA editing in AD, specific to the hippocampus and the GluA2 site. Deficient editing also characterized the hippocampus of apolipoprotein ε4 allele carriers, regardless of clinical diagnosis. In AD, messenger RNA expression of neuronal markers was decreased in the hippocampus, and expression of the Q/R-site editing enzyme ADAR2 was decreased in caudate. These findings provide a link between neurodegenerative processes and deficient RNA editing of the GluA2 Q/R site, and may contribute to both diagnosis and treatment of AD.",

keywords = "ADAR, AMPA, Alzheimer's disease, ApoE, Caudate, GluA2, Glutamate, Hippocampus, Neurodegeneration, Postmortem, Primer extension, RNA editing",

author = "Inna Gaisler-Salomon and Efrat Kravitz and Yulia Feiler and Michal Safran and Anat Biegon and Ninette Amariglio and Gideon Rechavi",

note = "Funding Information: This work was supported in part by grants from the Flight Attendant Medical Research Institute , The Molecular Basis of Human Disease I-CORE (Israeli Centers of Research Excellence) and by the Israel Science Foundation (grant numbers 365/06 and 1942/08 ), and the Israel Ministry for Science and Technology (Scientific Infrastructure Program). Gideon Rechavi holds the Djerassi Chair in Oncology at the Sackler Faculty of Medicine, Tel Aviv University. The authors thank Noa Eilat for her help with proofreading the manuscript.",

year = "2014",

month = aug,

doi = "10.1016/j.neurobiolaging.2014.02.018",

language = "English",

volume = "35",

pages = "1785--1791",

journal = "Neurobiology of Aging",

issn = "0197-4580",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease

AU - Gaisler-Salomon, Inna

AU - Kravitz, Efrat

AU - Feiler, Yulia

AU - Safran, Michal

AU - Biegon, Anat

AU - Amariglio, Ninette

AU - Rechavi, Gideon

N1 - Funding Information: This work was supported in part by grants from the Flight Attendant Medical Research Institute , The Molecular Basis of Human Disease I-CORE (Israeli Centers of Research Excellence) and by the Israel Science Foundation (grant numbers 365/06 and 1942/08 ), and the Israel Ministry for Science and Technology (Scientific Infrastructure Program). Gideon Rechavi holds the Djerassi Chair in Oncology at the Sackler Faculty of Medicine, Tel Aviv University. The authors thank Noa Eilat for her help with proofreading the manuscript.

PY - 2014/8

Y1 - 2014/8

N2 - Adenosine to inosine (A-to-I) RNA editing is a base recoding process within precursor messenger RNA, catalyzed by members of the adenosine deaminase acting on RNA (ADAR) family. A notable example occurs at the Q/R site of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor subunit GluA2. Abnormally, low editing at this site leads to excessive calcium influx and cell death. We studied hippocampus and caudate samples from Alzheimer's disease (AD) patients and age-matched healthy controls, using direct sequencing and a high accuracy primer-extension technique to assess RNA editing at the Q/R GluA2 site. Both techniques revealed lower, more variable RNA editing in AD, specific to the hippocampus and the GluA2 site. Deficient editing also characterized the hippocampus of apolipoprotein ε4 allele carriers, regardless of clinical diagnosis. In AD, messenger RNA expression of neuronal markers was decreased in the hippocampus, and expression of the Q/R-site editing enzyme ADAR2 was decreased in caudate. These findings provide a link between neurodegenerative processes and deficient RNA editing of the GluA2 Q/R site, and may contribute to both diagnosis and treatment of AD.

AB - Adenosine to inosine (A-to-I) RNA editing is a base recoding process within precursor messenger RNA, catalyzed by members of the adenosine deaminase acting on RNA (ADAR) family. A notable example occurs at the Q/R site of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor subunit GluA2. Abnormally, low editing at this site leads to excessive calcium influx and cell death. We studied hippocampus and caudate samples from Alzheimer's disease (AD) patients and age-matched healthy controls, using direct sequencing and a high accuracy primer-extension technique to assess RNA editing at the Q/R GluA2 site. Both techniques revealed lower, more variable RNA editing in AD, specific to the hippocampus and the GluA2 site. Deficient editing also characterized the hippocampus of apolipoprotein ε4 allele carriers, regardless of clinical diagnosis. In AD, messenger RNA expression of neuronal markers was decreased in the hippocampus, and expression of the Q/R-site editing enzyme ADAR2 was decreased in caudate. These findings provide a link between neurodegenerative processes and deficient RNA editing of the GluA2 Q/R site, and may contribute to both diagnosis and treatment of AD.

KW - ADAR

KW - AMPA

KW - Alzheimer's disease

KW - ApoE

KW - Caudate

KW - GluA2

KW - Glutamate

KW - Hippocampus

KW - Neurodegeneration

KW - Postmortem

KW - Primer extension

KW - RNA editing

UR - http://www.scopus.com/inward/record.url?scp=84899946185&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2014.02.018

DO - 10.1016/j.neurobiolaging.2014.02.018

M3 - Article

C2 - 24679603

AN - SCOPUS:84899946185

SN - 0197-4580

VL - 35

SP - 1785

EP - 1791

JO - Neurobiology of Aging

JF - Neurobiology of Aging

IS - 8

ER -

Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this